COMMON STOCK | 6. COMMON STOCK a) Issuances On February 14, 2017, the Company completed the first tranche closing (the "First Tranche Closing") of a non-brokered private placement of units (each a “Unit”) announced January 27, January 30, February 7, and February 10, 2017 (the “February 2017 Offering”). The First Tranche Closing consisted of the issuance of 3,860,800 Units at a price of C$0.70 per Unit, for gross proceeds of C$2.7 million. Each Unit consists of one Common Share and one transferable Common Share purchase warrant (each whole such warrant a "Warrant"), with each Warrant entitling the holder thereof to acquire one additional Common Share at a price of C$0.85 for a period of 36 months from their date of issuance. On February 28, 2017, the Company completed the second and final tranche closing (the "Final Closing") of the February 2017 Offering. The Final Closing consisted of the issuance of 3,503,989 units including 2,964,682 units dated February 21, 2017, and 539,307 units dated February 28, 2017 (collectively, the “Final Closing Units”), at a price of C$0.70 per Unit, for gross aggregate proceeds of C$2.5 million. Each Final Closing Unit consists of one Common Share and one transferable Common Share purchase warrant (a "Warrant"), with each Warrant entitling the holder thereof to acquire one additional Common Share at a price of C$0.85 for a period of three years from Unit issuance. The Company paid cash commissions of C$88 and issued 78,342 broker warrants (having the same terms as the Warrants) in connection with the Final Closing to brokers outside of the United States. The broker warrants were valued at C$26 using a risk-free rate of 0.75%, expected volatility of 81.27% and expected life of three years. b) Stock Options The Company has a rolling stock option plan (the “Plan”) whereby the Company may grant stock options to executive officers and directors, employees, and consultants at an exercise price to be determined by the board of directors, provided the exercise price is not lower than the greater of (i) the last closing price of the Company’s common shares on the TSX and (ii) the volume weighted average closing price of the Company’s common shares on the TSX for the five days immediately prior to the date of grant. The Plan provides for the issuance of up to 10% of the Company’s issued Common Shares as at the date of grant with each stock option having a maximum term of ten years. The board of directors has the exclusive power over the granting of options and their vesting provisions. Stock option transactions are summarized as follows: Number of Weighted Balance, June 30, 2016 11,465,000 $ 0.69 Granted 6,360,000 0.78 Exercised (150,000 ) 0.62 Cancelled/expired (650,000 ) 0.76 Balance, March 31, 2017 17,025,000 $ 0.72 The following table summarizes the information and assumptions used to determine option costs for the nine-month period ended March 31, 2017: Fair value per option granted during the period (C$) $ 0.42 Risk-free interest rate 0.75 % Expected dividend yield 0 % Expected stock price volatility (historical basis) 92.93 % Expected option life in years 2.15 The following table summarizes information about stock options outstanding at March 31, 2017: Exercise Expiry date Number Aggregate Number Aggregate $ 0.50 May 9, 2017 370,000 $ 89 370,000 $ 89 $ 0.62 January 19, 2021 5,275,000 633 3,956,250 475 $ 0.65 May 20, 2017 50,000 4 50,000 4 $ 0.65 July 28, 2017 1,250,000 113 1,250,000 113 $ 0.76 September 2, 2017 500,000 - 500,000 - $ 0.76 March 7, 2022 5,650,000 - - - $ 0.80 December 22, 2017 2,720,000 - 2,720,000 - $ 0.94 April 28, 2018 500,000 - 500,000 - $ 0.96 July 21, 2021 710,000 - 355,000 - Balance March 31, 2017 17,025,000 $ 839 9,701,250 $ 681 The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on the Company’s closing stock price of C$0.74 as of March 31, 2017, which would have been received by the option holders had all option holders exercised their options as of that date. In-the-money options vested and exercisable as of March 31, 2017, totaled 5,626,250. As March 31, 2017, there was $1,436 of unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a remaining weighted average period of approximately 1.4 years. c) Warrants Warrant transactions are summarized as follows: Warrants Weighted average Balance June 30, 2016 22,733,685 $ 0.74 Granted 8,333,801 0.86 Exercised (3,447,137 ) 0.65 Expired (7,011,263 ) 0.79 Balance, March 31, 2017 20,609,086 $ 0.79 As discussed above under Note 6a, the Company granted 7,364,789 warrants and 78,342 broker warrants in conjunction with the February 2017 Offering. In addition, as discussed above under Note 5, the Company granted 890,670 First Tranche Increase warrants to Lind in connection with the funding of the First Tranche Increase. At March 31, 2017, the Company has outstanding exercisable warrants, as follows: Number Exercise Expiry Date 3,125,000 0.72 December 22, 2018 9,150,285 0.75 January 19, 2019 3,860,800 0.85 February 14, 2020 2,964,682 0.85 February 21, 2020 617,649 0.85 February 28, 2020 890,670 0.90 March 31, 2020 20,609,086 |